Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Merck Serono Backs $250,000 MS Website

By Drug Discovery Trends Editor | October 2, 2013

Merck Serono, the biopharmaceutical division of Merck, is the founding supporter of the newly launched Multiple Sclerosis (MS) Resource Centre website developed by Elsevier, B.V. of the Netherlands. Merck Serono helped established the MS Resource Centre through a $250,000 unrestricted grant to Elsevier, B.V. to develop and launch the website, which will provide high quality, balanced and scientifically valid information to health care providers.
 
“Merck Serono is proud to have provided the necessary foundation for Elsevier to develop this website that aims to provide clinicians with access to the latest literature on multiple sclerosis,” said Thorsten Eickenhorst, senior vice president and chief medical officer at EMD Serono Inc., a subsidiary of Merck. “We are committed to supporting organizations that invest in the understanding and treatment of multiple sclerosis, and share our goal of improving patient care.”
 
The MS Resource Centre is a medical education platform for healthcare providers hosted by Elsevier’s new peer-reviewed journal, Multiple Sclerosis and Related Disorders. This website will afford the MS community numerous benefits, including access to taped lectures, video interviews with leaders in the field, a congress planner and key articles reporting on breakthrough findings by highly regarded authors. Timothy Vartanian, professor at the Brain and Mind Research Institute and the Department of Neurology, Weill Cornell Medical College, Cornell University is the editor of the Resource Center.
 
The site will be launched at the ECTRIMS 2013 conference, Oct. 2 to 5, in Copenhagen, Denmark.
 
Date: October 1, 2013
Source: Merck KGaA

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50